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ABSTRACT 
 
Anti-mycobacterial bioactivity of non polar compounds from Coleus atropurpureus L. 
Benth was carried out. An cyclic ester terpenoid, 2’, 5’-dimethyl benzopelargonolactone  
has been isolated from the chloroform fraction from the leaves of Coleus atropurpureus L. 
Benth, and its structure was determined by spectroscopic evidences including FTIR and 
2D NMR and compared to previous data. The in vitro anti-mycobacterial activities of its 
whole extracts, chloroform  extract, and pure compound were evaluated by testing their 
MIC (minimal inhibitory concentration). The isolate alone was active against M. 
tuberculosis with MIC at concentration 200 µg/mL, and  could also increase the sensitivity 
of this pathogen to rifampicin  drug at concentration 0.5 µg/mL. These studies suggest 
that anti-mycobacterial 2’, 5’-dimethyl benzopelargonolactone in combination with 
rifampicin may play an important role for alternative treatment combination against M. 
tuberculosis strain H37Rv. Further studies aimed to structural modification and semi-
synthesis of active compound which exhibited increasing anti-mycobacterial activities, 
need to be carried out in the future. 
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INTRODUCTION 
 
Tuberculosis is a disease that causes a high 
mortality every year to the world’s population. 
According to WHO, 1.1 million people died from 
TB in 2010 among HIV negative cases, and an 
additional 0.35 million deaths among people 
who were HIV-positive were registered. In the 
recently year there were estimated 8.8 million 
incident cases of TB globally. Although TB can 
be treated and even cured with chemotherapy, 
treatment is exceedingly lengthy and takes 6-9 
months[1]. In addition to significant toxicity, 
lengthy therapy also causes poor patient 
compliance, which is a frequent cause for 
selection of drug resistant and often deadly 
multidrug resistant TB (MDR-TB) bacteria[2].  
Additionally, the number of cases of multi-drug 
resistant tuberculosis (MDRTB) was 440,000 in 
2008 and by  2010, 58 countries and territories 
had reported at least one case of extensively 
drug-resistant tuberculosis (XDR-TB)[3].   
Tuberculosis with a different drug resistance 
(DDRTB) involves M. tuberculosis strains 
displaying mono- or poly-resistance which is 
not including associated resistance against 
isoniazid and rifampicin[4]. Very recently, 
patterns of resistance to commonly used anti-
tuberculosis drugs among M. tuberculosis 
complex isolates from patients attending 
government urban TB diagnostic in Makassar, 
the capital of the South Sulawesi Province in 
Indonesia, was found to be highly potential risk 
factors for MDR-TB[5]. According to these data, 
strong efforts should be directed to find new 
antimycobacterial drugs, taking into account 
that MDR-TB and XDR-TB represent serious  
threats to the world’s population health. To 
eliminate this situation and problem from every 
corner of the world, a safe, non-toxic and cost 
effective drug with novel mode of action is 
immediately required. The need of new leads 
for such  drugs, sustain to consider natural 
products from plants as sources of 
antimycobacterial therapeutically useful 
substances[6]. Plants are good source of a wide 
variety of compounds, such as phenolic 
compounds, terpenoids, steroids, alkaloids, 
nitrogen containing compounds, vitamins, and 
primary or secondary metabolites which have 
antioxidant, antimicrobial, anti-inflammatory, 
antitumor, antimutagenic, anti-carcinogenic, 
and diuretic activities. Natural product from 
plants are important for pharmacological 
research and drug development, not only 
when the plant constituents are used directly 
as therapeutic agents, but also as starting 
materials for the synthesis of drugs or as 
model for the lead compounds[7].  
Among the plants known for medicinal 
value, the plants of the genus Coleus 
belonging to the family Lamiaceae or Labiatae 
are well known for their therapeutic potentials. 
The plants of Lamiaceae are usually aromatic 
and known for kitchen herbs like Rosemary  
and Ocimum sanctum. Many of the plants of 
this family are used in traditional medicine 
because of their antimicrobial, antioxidant, 
antiseptic and other pharmacological activities. 
Coleus is a large and wide spread genus 
containing 300 species and is found in different 
parts of tropical Africa, Australia and Asia, 
especially in Indonesia[8,9].  Coleus species are 
found as herbs, subshrubs or shrubs. They are 
often succulent with opposite leaves. In 
flourescence is terminal or in the upper leaf 
axils is in compact cymose clusters. Coleus 
atropurpureus L. Benth, one of the plants of 
genus Coleus which is native to Indonesia, 
especialy in South Sulawesi Province. The 
leaves  decoction is indicated for the traditional 
treatment of bronchitis, hemorrhoids, 
antioxidants, and  tuberculosis[10,11] 
Nevertheless, only few studies have focused 
on the biological  activity of  the  extracts and 
components of the leaves  of Coleus. The 
methanol extract of the bark showed in vitro 
bactericidal activity against Staphylococcus 
aureus, Escherichia coli, Salmonella 
typhimurium, Pseudomonas aeruginosa, 
Klebsiella pneumoniae and Enterococcus 
faecalis [12].     
Little is also known about the chemical 
constituents of the plant. The essential oil 
composition was studied[13, 14] and saponins 
were isolated from the seeds[15].     From an 
aqueous extract, catechins were identified as 
the  main components[16]. The objectives of the 
present study were to evaluate the in vitro 
antimycobacterial activity of the chloroform  
extract obtained from the leaves  of Coleus 
atropurpureus L. Benthand characterization of 
components by Spectroscopy FTIR and 2D 
NMR, in order to improve the knowledge about 
Int J Pharm Bio Sci 2014 Jan; 5(1): (B) 758 - 764 
 
 
This article can be downloaded from www.ijpbs.net 
B - 760 
 
the chemical  structural  of compound from the 
leaves  of Coleus atropurpureus L. Benth  and 
to explore its potential as a source of new drugs 
against M. tuberculosis. The election of the 
Spectroscopy FTIR and NMR technique was 
supported by the fact that the extract was 
obtained from the leaves of Coleus 
atropurpureus L. Benth, which possesses  a 
high content  of  terpenoid compounds. In this 
study, we report for the first time the isolation, 
purification, and structural determination of 
cyclic ester terpenoid, 2’, 5’-dimethyl 
benzopelargonolactone from the leaves of 
Coleus atropurpureus L. Benth. We also tested 
the activity of 2’, 5’-dimethyl 
benzopelargonolactone alone and in 
combination with the anti-tuberculosis drug 
rifampicin against M. tuberculosis  strain H37Rv 
(ATCC 27294) to increase sensitivity to anti-
tuberculosis drugs. 
 
MATERIALS AND METHODS 
 
Materials 
The leaves of Coleus atropurpureus L. Benth 
was collected in the region of Malino and Tana 
Toraja, South Sulawesi Province, Indonesia.  
Samples plant  identification was conducted in 
Plant Taxonomy Laboratory Faculty of Natural 
Sciences Hasanuddin University, Indonesia. 
Chloroform, rifampicin, and methanol were 
purchased from Sigma Chemical Co. (USA). 
 
Extraction and Isolation of active 
compound 
Dry powder of 3.0 kg of the leaves of Coleus 
atropurpureus L. Benth, was macerated with 
MeOH for 72 h, filtered, and solvent 
evaporated to obtain a dark brown extract 
amounting 59.28 g. The extracts were 
partitioned with chloroform  resulting in 9.96 g 
product. The chloroform extract was 
fractionated by VLC and produced ten major 
fractions (I-X). Colourless red precipitate found 
in the second fraction was filtered by filtration 
resulting in 58.3 mg product. Purity test was 
performed by TLC analysis using three solvent 
systems.  
 
Instrumentation 
FTIR spectra determination was done with a 
Shimadzu  spectrometer (Japan). NMR spectra 
of 1H, 13C and HMBC were obtained using a 
Bruker, Germany DPX-500 spectrometer at 
300 MHz (1H) and 125 MHz (13C) in CDCl3 
using TMS as internal reference. Separations 
and identification of compound were conducted 
with VLC by Merck Si gel 60 (230-400 mesh), 
and TLC on aluminum or glass plates coated 
with Merck Si gel 60 F254 and thickness of 
0.25 mm. 
 
Anti-mycobacterial  activity assays 
For the initial bioactivity screening, standard 
colony assays on Löwenstein-Jensen (LJ) 
medium were performed to assess the anti-
mycobacterial activity of methanol whole 
extract, chloroform fraction, and compound I 
with the final concentrations of 200 µg/mL, 
respectively, using the strain M. tuberculosis 
H37Rv (ATCC 27294) and solvent DMSO as 
negative control plus rifampicin as positive 
control.  For testing the anti-mycobacterial 
activity and MIC value of compound I and in 
combination with rifampicin, the strain M. 
tuberculosis H37Rv (ATCC 27294) were grown 
on Middlebrook 7H19-OADC (oleic acid, 
albumin, dextrose, catalase) (Difco 
Laboratories, USA) at 37 °C for 3 weeks until 
midlog phase. The turbidity of culture were 
adjusted with 7H9 broth to a 0.5 McFarland 
standard using a nephelometer, and cell 
cultures was inoculated on 4 mL MGIT 
medium[17,18], using solvent (DMSO) as 
negative control, rifampicin  (0, 0.5, 1.0, and 
2.0 µg/mL), and combination with compound I 
were indicated. Tubes were incubated at 37 °C 
and inhibition growth documented after 3 days; 
MGIT tubes were removed from the incubator 
and placed on a 365 nm UV transilluminator 
(micro MGIT reader). It is important to read the 
tube everyday beginning on day 3, until results 
can be interpreted. The positive tubes results if 
there was high level fluorescens from the 
bottom of the tube when the tube put in the 
micro MGIT reader and negative tubes showed 
low level or no flourescens. . Once the MGIT 
growth control is positive, the drug-containing 
tubes will be read for interpreting results. We 
could start read the MGIT tube with containing 
drug (first line drugs or second line drugs) on 
the same day when MGIT GC is positive and 
interpret the result for up the third days, not to 
exceed fourteen days. . If the MGIT GC tube is 
not positive by the twelfth day of the test, the 
test is invalid. Interpret the MGIT result as 
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susceptible if the drug-containing tube does not 
fluoresce within two days of onset of 
fluorescence in the GC tube. Interpret the 
MGIT result as resistant if the drug-containing 
tube fluoresces on or within two days of the 
day of onset of fluorescence in the GC tube. 
When interpreting resistance, finalize the result 
as soon as the MGIT GC and the drug-
containing tubes fluoresce. All inoculated MGIT 
tubes after 56 days or negative results should 
be autoclaved prior to disposal. For positive 
MGIT media results should add disinfectant (5 
% Vesphene) before put in the autoclave bag. 
MGIT tubes are kept in the autoclave bag 
place in the autoclave. After finish autoclaving, 
send them for the incineration. The growth 
control tube was compared to the positive and 
negative controls; positivity was indicated by 
bright orange fluorescence on the bottom of 
the tube and an orange reflection at the 
meniscus; negative tubes on the other hand 
showed low level or no fluorescence. The 
assays was conducted in duplicates and 
repeated three times to produce representative 
experimental data.  
 
RESULTS AND DISCUSSION 
 
The amount 59.28 g of methanol extract of the 
dried and powdered form of the leaves of 
Coleus atropurpureus L., was partitioned with 
chloroform solvent. The chloroform fraction 
was further separated by silica gel 
chromatography and purified to obtain 
compound I. The compound obtained, 
compound I is an colourless red paste, giving 
an indication of terpenoid  on Liebermann-
Burchard test.  Its FTIR spectrum showed the 
absorption bands for aliphatic groups (2956, 
2927 and 2856), C=C aromatic (1598 and 
1579), =C-H aromatic (3068), CH2 (1463), CH3 
(1379), C=O from ester  groups in the molecule 
(1728, 1266) and while strong absorption band 
C-O-C (1072)  and disubstitution aromatic 
(742) were characterized as an cyclic ester 
terpenoid compound. The 13C NMR and DEPT 
spectrum exhibited 15 carbon signals (2×CH3, 
4×CH2, 6×CH including =C-H aromatic, 3×C 
including C=O), and  the molecular formula of 
compound I was deduced to be C15H20O2. The 
1H NMR spectrum (Table 1) observed the 
presence of two tertiary methyl groups on 
saturated carbons at 0.89 (3H, m) and 0.91 
(3H, m), also two unit isoprenoid of aliphatic 
signals at δ 1.43 (H-1’, 2H, d,  J = 5,8 Hz), 1.68 
(H2’, 1H, m), 1.31 (H3’, 2H, m), 1.35 (H-4’, 2H, 
m),   1.68 (H-5’, 2H, m), 4.21 (H-6’, 2H, m), 
1.30 (H-7’, 2H, m), 0.89 (H-8’, 3H, m), 1.41 
(H9’, 2H, m), 0.91 (H-10’, 3H, m). Two signals 
methyl carbons at d 14.2 and 11.1 in the 13C 
NMR (Table 1) spectrum indicated that 
compound I belongs to the cyclic ester 
terpenoid,  and four methylen signals carbons 
at  δ 68.3 ppm (C-6’), 30.5 ppm (C-4’), 23.1 
ppm (C-3’), 27.1 ppm (C-1’), and six methyn 
signals at  δ 38.9 ppm (C-5’), 38.9 ppm (C-2’), 
128.9 ppm (C-3 and C-6), 131.0 ppm (C-4 and 
C-5).  The correlation of 13C carbon with 1H  
proton were observed in the HMBC and COSY 
spectrum (Table 1). Based on the data 
description above and by comparison of their 
physico-chemical and spectroscopic data with 
those of previously known related 
compounds[19], the molecular structure of 
compound I is in Figure 1 with name of 2’, 5’-
dimethyl benzopelargonolactone. 
  
Table 1 
1H (300 MHz) and 13C (125 MHz) NMR data of compound I in CDCl3 
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In the first, to screening antimycobacterial activity of all fractions, including compound I at 
concentrations 200 µg/mL  was measured by incubating with  the  mycobacterial cells on LJ 
medium. MeOH fraction at concentration 200 µg/mL was able to decrease mycobacterial cells 
growth, where as chloroform fraction and compound I in the same concentration, like rifampicin as 
positive control with no colony growth of M. tuberculosis on LJ medium (data not shown). To 
identify the MIC value  of  compound I,   anti-mycobacterial  activity   of  this   compound   against   
 
 
 
Figure 1 
Structure of 2’,5’-dimethyl benzopelargonolactone  
(I) from the leaves of Coleus atropurpureus L. 
 
Table 2 
Effect of compound I in combination with rifampicin in MGIT medium on     
growth inhibition of M. tuberculosis H37Rv (ATCC 27294) strain. 
 
 
 
M. tuberculosis  test was performed with MGIT 
medium. The combinations  of compound   I 
and      rifampicin    were  tested    in     the  
anti-mycobacterial assay described above by a 
checkerboard method in order to identify those 
combinations that could enhance bioactivity 
effect. The antimycobacterial activity of 
compound I at different concentrations 0, 100, 
200, and 400 µg/mL  in combination with 
rifampicin at variation concentrations 0, 0.5, 
1.0, and 2.0 µg/mL was measured by 
incubating the  mycobacterial cells on MGIT 
medium. Compound I alone at concentration 
100 µg/mL was not able to inhibited 
mycobacterial cells growth.  Furthermore, at  
concentration 200 and 400 µg/mL showed 
significant inhibition of growth of M. 
tuberculosis (Table 2). The combinations with 
the rifampicin at concentration 0.5 µg/mL  was 
able to exhibit enhanced mycobacterial effect 
at the lowest concentration (100 µg/mL) of 
compound I (Table 2). The results of this study 
demonstrated  that  compound I  was activated 
against M. tuberculosis when used in 
combination with other antimycobacterial 
agents (rifampicin), and increased the 
sensitivity of the anti-TB drug. This result was 
in accordance with previously reported 
research by Woldemichael  et al (2003), where 
terpenoid compounds from Calceolaria 
pinnifolia (Scrophulariaceae)  showed  
significant inhibition of growth of M. 
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tuberculosis with MIC values 128 µg/mL, 
although mechanism of anti-mycobacterial  
action by direct and/or indirect  of terpenoid 
compounds is not fully clear, but is speculated 
to involve membrane disruption of 
mycobacterial cells by lipophilic compounds 
[18,20, 21]. 
 
CONCLUSION 
 
Compound I, an cyclic ester terpenoid, 2’, 5’-
dimethyl benzopelargonolactone  has been 
isolated from the chloroform fraction from 
leaves of Coleus atropurpureus L. Benth. The 
compound was not only active against M. 
tuberculosis with MIC values 200 µg/mL, but 
also could activated the sensitivity of rifampicin 
drug for treated patient with TB. In conclusion, 
our results demonstrated that the activity 
rifampicin  drug could be activated and 
enhanced through administration with 2’, 5’-
dimethyl benzopelargonolactone. Further 
studies aimed to structural modification and 
semi-synthesis of compound I which exhibited 
increasing anti-mycobacterial activities, and 
also  using in vivo methods are required to 
explore the compound responsible for the 
activity which might prove important for 
improved therapies for the treatment of 
tuberculosis disease. 
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